Results 101 to 110 of about 32,676 (224)

Association of SGLT2 Inhibitor With Stroke in Type 2 Diabetes With Diabetic Retinopathy: A Multicenter Electronic Health Record Data Study

Diabetes, Obesity and Metabolism, Volume 28, Issue 7, Page 5614-5626, July 2026.
ABSTRACT Aims Diabetic retinopathy (DR) is linked to elevated risks of cerebrovascular diseases. Whether sodium‐glucose cotransporter‐2 inhibitors (SGLT2i) reduce stroke risk in patients with type 2 diabetes (T2D) and DR remains uncertain. Materials and Methods We conducted a retrospective cohort study using the TriNetX Research Network.
Kuo‐En Chen, Po‐Chun Wang, Hui‐An Lin, Sheng‐Feng Lin   +3 more
wiley   +1 more source

A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban

Clinical Pharmacology: Advances and Applications, 2014
Charles Frost,1 Yan Song,1 Yu Chen Barrett,1 Jessie Wang,2 Janice Pursley,3 Rebecca A Boyd,4 Frank LaCreta1 1Exploratory Clinical and Translational Research, 2Exploratory Development Global Biometric Sciences, 3Analytical and Bioanalytical Development ...
Frost C, Song Y, Barrett YC, Wang J, Pursley J, Boyd RA, LaCreta F   +6 more
doaj  

Safety profile of rivaroxaban in first-time users treated for venous thromboembolism in four European countries.

PLoS ONE
BackgroundThe European rivaroxaban post-authorization safety study evaluated bleeding risk among patients initiated on rivaroxaban or vitamin K antagonists for the treatment and secondary prevention of venous thromboembolism in routine clinical practice ...
Ana Ruigómez, Tania Schink, Annemarie Voss, Ron M C Herings, Elisabeth Smits, Karin Swart-Polinder, Yanina Balabanova, Gunnar Brobert, Kiliana Suzart-Woischnik, Luis Alberto García Rodríguez   +9 more
doaj   +1 more source

Effect of Co-Administration of Rivaroxaban and Clopidogrel on Bleeding Time, Pharmacodynamics and Pharmacokinetics: A Phase I Study

Pharmaceuticals, 2012
Dual antiplatelet therapy with acetylsalicylic acid and a thienopyridine, such as clopidogrel, is effective for the secondary prevention of cardiovascular events in patients with acute coronary syndrome, but there is still a substantial residual risk of ...
Michael Becka, Wolfgang Mück, Stephan Schwers, Dagmar Kubitza   +3 more
doaj   +1 more source

Rivaroxaban [díptic]

, 2018
Anticoagulants orals d’acció directa; Rivaroxaban; MedicamentsAnticoagulantes orales de acción directa; Rivaroxaban; MedicamentosDirect-acting oral anticoagulants; Rivaroxaban; MedicinesPreguntes i respostes sobre l’anticoagulant oral d’acció directa ...

core  

Trends and variation in the use of andexanet alfa for the reversal of direct oral anticoagulants in NHS trusts in England

British Journal of Clinical Pharmacology, Volume 92, Issue 6, Page 1607-1613, June 2026.
Abstract Aims Andexanet alfa was recommended by the National Institute for Health and Clinical Excellence (NICE) as an option in the management of life‐threatening gastrointestinal bleeding in patients taking apixaban or rivaroxaban in May 2021. A recent UK‐wide survey of local hospital protocols for the use of andexanet alfa suggested that practice ...
Louis Fisher, Richard Buka, Rosalind Byrne, Stephen Black, Helen J. Curtis, Christopher Wood, Andrew Brown, Sebastian Bacon, Richard Croker, Ben Goldacre, Brian MacKenna, Victoria Speed   +11 more
wiley   +1 more source

In Vivo pharmacokinetic interactions of ribociclib with rivaroxaban and apixaban in rats: implications for increased drug exposure and dose adjustments

Frontiers in Pharmacology
BackgroundApixaban (API) and rivaroxaban (RIVA) are orally available inhibitors of coagulation factor Xa and are commonly used to treat cancer-related venous thrombosis.
Zihan Liu, Zihan Liu, Wenyu Du, Wenyu Du, Qimin Wang, Zhi Wang, Jing An, Yinling Ma, Zhanjun Dong, Ying Li   +9 more
doaj   +1 more source

Rivaroxaban for venous thromboembolism prevention after major orthopedic surgery: translating trial data into routine clinical practice

, 2017
Jan Beyer-Westendorf,1 Patrick Mouret,2 Alexander GG Turpie3 1Thrombosis Research and Angiology, Dresden University Clinic, Dresden, Germany; 2Orthopedic Clinic, Klinikum Frankfurt Höchst GmbH, Frankfurt, Germany; 3Department of Medicine, General ...
Mouret P, Turpie AGG, Beyer-Westendorf J
core  

Diagnostic and Therapeutic Challenges in Statin‐Induced Necrotizing Autoimmune Myopathy in an Elderly Patient: A Rare Case Report

Clinical Case Reports, Volume 14, Issue 6, June 2026.
ABSTRACT We present the case of a 78‐year‐old woman with metabolic syndrome and a history of multiple ischemic strokes who developed progressive symmetrical proximal muscle weakness, predominantly affecting the lower extremities, while on atorvastatin.
Nischal Shrestha, Abdirahman Hassan, Jennifer Ann Evans   +2 more
wiley   +1 more source

A comparative study of the clinical benefits of rivaroxaban and dabigatran in patients with nonvalvular atrial fibrillation with high bleeding risk

Frontiers in Cardiovascular Medicine
ObjectiveRivaroxaban and dabigatran are approved to reduce the risk of stroke in patients with nonvalvular atrial fibrillation (NVAF). However, the clinical benefits of rivaroxaban and dabigatran in people with high bleeding risk are unclear.MethodsA ...
Penghui Liu
doaj   +1 more source